Novartis v. Dr. Reddy’s: ENTRESTO® Patent Battle Ends After 2,058 Days
Novartis AG filed suit against Dr. Reddy’s Laboratories and eleven other generic manufacturers in the District of Delaware, asserting four patents covering ENTRESTO® (sacubitril/valsartan) heart failure tablets. After more than five and a half years of litigation, the parties agreed to dismiss the proceeding, each side bearing its own costs.
Multi-Defendant ENTRESTO® ANDA War Ends by Agreement in Delaware
Novartis AG filed this Hatch-Waxman infringement action on 29 October 2019 before Judge Richard G. Andrews in the District of Delaware, asserting four patents — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — against twelve defendants seeking approval to market generic versions of ENTRESTO® tablets (sacubitril/valsartan) in three dose strengths: 24/26 mg, 49/51 mg, and 97/103 mg. ENTRESTO® is one of the most commercially significant heart failure drugs in the global market, making its patent portfolio a high-stakes target for generic challengers.
The case closed on 17 June 2025 by agreed dismissal under Fed. R. App. P. 42(b), with each side bearing its own costs. The agreed-upon cost allocation is a notable feature: neither party accepted liability for the other’s legal expenses, which is consistent with a negotiated resolution rather than a clear-cut adjudication on the merits. The precise terms of any underlying commercial agreement — including consent-judgment entry dates, authorised-generic arrangements, or royalty provisions — are not reflected in the public record.
A litigation span of 2,058 days — nearly five years and eight months — is well above typical ANDA case timelines, likely reflecting the complexity of coordinating twelve defendants across multiple corporate families (Hetero, MSN, Mylan, Zydus, Novugen, and Dr. Reddy’s), as well as the technical breadth of four distinct patents covering the sacubitril/valsartan active ingredient, formulation, and synthesis. The mutual cost-bearing arrangement and absence of any merits ruling suggest the parties reached a private accommodation; the specific terms remain undisclosed.
Filing to Case Dismissed in 2058 days
2,058 days — well above the median ANDA case duration in Delaware, suggesting protracted multi-defendant coordination
Agreed dismissal: what the order means for Novartis and the generic defendants
Fed. R. App. P. 42(b) dismissal by agreement
The order cites Fed. R. App. P. 42(b), which governs voluntary dismissal at the appellate level, though invoked here at district court level by stipulation. An agreed dismissal of this type terminates the proceeding without a merits ruling. No finding of infringement, validity, or invalidity was entered. This leaves the underlying patent claims legally intact and unchallenged by any court judgment from this docket.
No merits ruling enteredNovartis’s ENTRESTO® patents survive without invalidation
Because the case was dismissed by agreement rather than adjudicated, none of the four asserted patents were declared invalid or unenforceable by this court. Novartis retains the ability to enforce these patents against other parties. Any market-entry rights granted to the defendants would flow from a private agreement not reflected in the public record. This outcome is consistent with a negotiated settlement, potentially including a licensed entry date.
Patents intact — terms undisclosedDefendants avoided adverse merits ruling — entry terms private
The twelve generic defendants — spanning Hetero, MSN, Mylan, Zydus, Novugen, and Dr. Reddy’s — secured dismissal without a court finding of infringement. This avoids the 30-month stay consequence of a final judgment. However, the agreed cost split and absence of any fee award suggests neither side claimed a clear victory. The specific conditions under which generics may enter the sacubitril/valsartan market remain undisclosed.
No infringement findingPrivate settlement raises market-entry uncertainty for follow-on generics
Where Hatch-Waxman cases resolve by agreed dismissal with undisclosed terms, subsequent ANDA filers face informational disadvantage: the scope of any licensed entry window or royalty arrangement is unknown. For the sacubitril/valsartan market — a multi-billion dollar franchise — even a short authorised-generic exclusivity window carries significant commercial value. Companies monitoring ENTRESTO® generics should track consent judgments filed in related Novartis dockets for pricing signals.
Market entry timing uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Global pharmaceutical innovator — holder of ENTRESTO® sacubitril/valsartan heart failure patentsSearch in Eureka ↗ |
| Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Indian and multinational generic pharmaceutical manufacturers seeking ANDA approval for sacubitril/valsartan tabletsSearch in Eureka ↗ |
| Co-Defendant | Novugen Pharma (Malaysia) Sdn. Bhd. | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Hetero USA, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Msn Life Sciences Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | MSN Laboratories Private Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Mylan Laboratories Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Dr. Reddy’s Laboratories, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Mylan, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Cadila Healthcare, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Zydus Pharmaceuticals (USA), Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hetero Labs Limited | Individual | Search in Eureka ↗ |
| Co-Defendant | Mylan Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christina Schwarz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Deanne E. Maynard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared L. Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Melinda R. Roberts | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas N. Kallas | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Whitney M. Howard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Autumn N. Nero | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Bryan D. Beel | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Christopher D. Jones | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant counsel | Stamatios Stamoulis | Attorney | Counsel for Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Perkins Coie LLP | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Defendant law firm | Stamoulis & Weinblatt LLC | Law Firm | Representing Dr. Reddy’s Laboratories, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal order records that the parties ‘having so agreed’ sought termination under Fed. R. App. P. 42(b), with costs to lie where they fall. The cost-neutral formulation is significant: it is neither a concession of infringement by the defendants nor a withdrawal of enforcement by Novartis. No validity, infringement, or enforceability findings attach to any of the four patents. For both sides, this preserves optionality — Novartis may enforce the patents elsewhere; defendants may rely on any private entry-date terms agreed off the record.
US8101659B2, US9388134B2, US8796331B2 & US8877938B2 — sacubitril/valsartan (ENTRESTO®)
The four asserted patents — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — collectively cover the compound, formulation, crystalline form, and synthesis of sacubitril/valsartan, the active combination in ENTRESTO®. Filed across application years spanning 2007 to 2014, the portfolio reflects a layered prosecution strategy designed to extend protection across multiple patent expirations. The technology domain is cardiovascular pharmaceutical chemistry, specifically the angiotensin receptor-neprilysin inhibitor (ARNi) class — a mechanism that had no approved therapeutic predecessor when ENTRESTO® launched in 2015.
ENTRESTO® generated approximately $6 billion in global sales in 2023, making this patent portfolio one of the most commercially valuable in the cardiovascular drug space. The breadth of the four-patent assertion — compound through formulation — means any generic entrant must successfully design around or invalidate claims at multiple levels of abstraction. For competitors in the heart failure drug sector, the survival of all four patents without invalidation in this case marginally raises the bar for generic entry, though the undisclosed settlement terms may have already established an agreed entry date for the named defendants.
Should you run an FTO against US8101659B2 and the ENTRESTO® patent family?
Any pharmaceutical company developing a generic, biosimilar, or follow-on formulation of sacubitril, valsartan, or the combined sacubitril/valsartan salt complex should conduct a freedom-to-operate analysis against all four patents asserted in this case. This applies equally to ANDA filers, 505(b)(2) applicants, and companies developing next-generation ARNi compounds that share structural features with sacubitril. The compound patent (US8101659B2) and its continuation siblings cover the core chemical entity; formulation and process patents extend the risk surface further.
PatSnap Eureka’s FTO Search Agent can map your candidate compound or formulation against the claim scope of all four ENTRESTO® patents simultaneously, flag prosecution history estoppel risks from the USPTO file wrappers, and surface related global equivalents in EMA and other jurisdictions. Given that this litigation ran for 2,058 days without a merits ruling, an early Eureka FTO analysis can significantly reduce downstream litigation exposure by identifying design-around pathways before ANDA filing.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: sacubitril/valsartan and ARNi drug litigation
Explore related Hatch-Waxman ANDA infringement cases in Delaware District Court involving cardiovascular and heart failure pharmaceutical patents similar to the ENTRESTO® litigation.
What this case signals for the ENTRESTO® and heart failure drug IP landscape
Twelve generic challengers, four patents, and five-plus years of litigation — the ENTRESTO® case signals how Novartis manages its blockbuster franchise against generic entry.
Multi-defendant ANDA cases routinely resolve by private agreement, not judgment
This dismissal — with each side bearing its own costs and no merits ruling — is consistent with the dominant resolution pattern in complex Hatch-Waxman litigation. Patent attorneys advising generic filers should anticipate negotiated outcomes and model licensing scenarios early, particularly where the innovator holds multiple overlapping patents on the same product.
Four-patent assertion strategy strengthens Novartis’s negotiating leverage
By asserting four patents covering different aspects of sacubitril/valsartan — compound, formulation, and synthesis — Novartis created multiple invalidity fronts for twelve defendants to contest simultaneously. This breadth likely drove litigation duration and increased the settlement value for any defendant seeking early resolution. R&D teams designing around ENTRESTO® should conduct FTO analysis against all four patents, not just the lead compound claim.
Novartis v Dr. — key questions answered
The case was dismissed by agreed order on 17 June 2025, with each side bearing its own costs. Novartis had asserted four patents covering ENTRESTO® (sacubitril/valsartan) against twelve generic defendants. No merits ruling on infringement, validity, or enforceability was entered.
Novartis asserted four patents: US8101659B2, US9388134B2, US8796331B2, and US8877938B2. These patents collectively cover the compound, formulation, crystalline form, and synthesis of sacubitril/valsartan across application filings spanning 2007 to 2014.
Twelve defendants were named, spanning multiple generic pharmaceutical groups: Dr. Reddy’s Laboratories, Hetero Labs and Hetero USA, MSN Life Sciences, MSN Laboratories, MSN Pharmaceuticals, Mylan Laboratories, Mylan Inc., Mylan Pharmaceuticals, Zydus/Cadila Healthcare, Zydus Pharmaceuticals USA, and Novugen Pharma (Malaysia).
No. The agreed dismissal contains no finding of invalidity, unenforceability, or non-infringement. All four asserted patents remain in force. The dismissal is consistent with a private negotiated resolution, the terms of which are not on the public record. Novartis retains the right to enforce these patents against other parties.
A litigation duration of approximately five years and eight months is above the typical median for ANDA cases in Delaware. It likely reflects the complexity of coordinating twelve defendants across six corporate families, the technical breadth of four overlapping patents, and the high commercial stakes of ENTRESTO®’s multi-billion dollar annual revenue. Such extended timelines are consistent with cases that ultimately resolve through negotiated settlement rather than trial.
PatSnap Eureka searches patents and litigation data to answer instantly.